Table 1. Baseline patient characteristics of TRACERx and BLCS cohorts.
SD standard deviation, BMI body mass index, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, SKM skeletal muscle
| TRACERx (N=651) | BLCS (N=420) | |
|---|---|---|
| Age, Mean (SD), years | 68.7 (9.12) | 64.53 (10.1) |
| BMI, mean (SD), kg/m2 | 26.7 (5.11) | 26.48 (5.4) |
| Weight, mean (SD), m | 75.0 (16.9) | 75.02 (18.2) |
| Height, mean (SD), m | 1.67 (0.1) | 1.68 (0.1) |
| VAT baseline, mean (SD), cm2 | 138 (98.7) | 145.5 (113.9) |
| SAT baseline, mean (SD), cm2 | 169 (94.3) | 190.5 (103.5) |
| SKM baseline, mean (SD), cm2 | 126 (34.5) | 133.6 (33.9) |
| Sex | ||
| Female | 286 (43.9%) | 198 (47.1) |
| Male | 365 (56.1%) | 222 (52.9) |
| Ethnicity | ||
| White-Caucasian | 411 (97.9) | |
| African American | 9 (2.1) | |
| Non-White | 36 (5.5%) | |
| White-British-Irish | 590 (90.6%) | |
| White-Other | 22 (3.4%) | |
| Missing | 3 (0.5%) | |
| Smoking status | ||
| Current Smoker | 89 (13.7%) | 155 (36.9) |
| Ex-Smoker | 513 (78.8%) | 216 (51.4) |
| Never Smoked | 49 (7.5%) | 49 (11.7) |
| NSCLC stage | ||
| IA | 131 (20.1%) | 203 (48.3) - all stage I |
| IB | 139 (21.4%) | |
| IIA | 124 (19.0%) | 63 (15.0) - all stage II |
| IIB | 113 (17.4%) | |
| IIIA | 138 (21.2%) | 154 (36.7) - all stage III |
| IIIB | 6 (0.9%) | |
| Histology | ||
| Adenocarcinoma | 362 (55.6%) | 223 (53.1) |
| Squamous cell carcinoma | 211 (32.4%) | 104 (24.8) |
| Other | 65 (10.0%) | 93 (22.1) |
| N/A | 13 (2.0%) | |
| Adjuvant treatment | ||
| Adjuvant | 227 (34.9%) | 229 (54.5) |
| No adjuvant | 408 (62.7%) | 191 (45.5) |
| Missing | 16 (2.5%) | |